KNG1 Protein (AA 390-644) (His tag)
-
- Target Alle KNG1 Proteine anzeigen
- KNG1 (Kininogen 1 (KNG1))
- Protein-Typ
- Recombinant
- Proteineigenschaft
- AA 390-644
-
Spezies
- Human
-
Quelle
- Escherichia coli (E. coli)
- Aufreinigungstag / Konjugat
- Dieses KNG1 Protein ist gelabelt mit His tag.
- Applikation
- SDS-PAGE (SDS)
- Sequenz
- SSRIGEIKEE TTVSPPHTSM APAQDEERDS GKEQGHTRRH DWGHEKQRKH NLGHGHKHER DQGHGHQRGH GLGHGHEQQH GLGHGHKFKL DDDLEHQGGH VLDHGHKHKH GHGHGKHKNK GKKNGKHNGW KTEHLASSSE DSTTPSAQTQ EKTEGPTPIP SLAKPGVTVT FSDFQDSDLI ATMMPPISPA PIQSDDDWIP DIQIDPNGLS FNPISDFPDT TSPKCPGRPW KSVSEINPTT QMKESYYFDL
- Aufreinigung
- SDS-PAGE
- Reinheit
- > 90 %
- Top Product
- Discover our top product KNG1 Protein
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.1-2 mg/mL
- Buffer
- 20 mM Tris-HCl based buffer, pH 8.0
- Lagerung
- -80 °C,4 °C,-20 °C
- Informationen zur Lagerung
- Store at -20°C, for extended storage, conserve at -20°C or -80°C. Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
-
- Target
- KNG1 (Kininogen 1 (KNG1))
- Andere Bezeichnung
- KNG1 (KNG1 Produkte)
- Synonyme
- BDK Protein, BK Protein, KNG Protein, Kng Protein, KNG2 Protein, fb64g01 Protein, wu:fb64g01 Protein, zgc:103569 Protein, kininogen Protein, bdk Protein, kng Protein, KNG1 Protein, IHRP Protein, KINKG Protein, KINKH Protein, Kng1 Protein, Kngk Protein, kininogen 1 Protein, kininogen 1 L homeolog Protein, inter-alpha-trypsin inhibitor heavy chain family member 4 Protein, kininogen 2-like 1 Protein, KNG1 Protein, Kng1 Protein, kng1 Protein, kng1.L Protein, ITIH4 Protein, Kng2l1 Protein
- Hintergrund
- 1 Kininogens are inhibitors of thiol proteases, (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes, (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action), (5) LMW-kininogen inhibits the aggregation of thrombocytes, (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
- Molekulargewicht
- 31.9 kDa
- UniProt
- P01042
- Pathways
- ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process
-